Phase I trial led by Dr. Nicholas Gulati tested topical diphencyprone for cutaneous neurofibromas in NF1. Safe and well tolerated, but only 1 of 12 patients showed partial response. A key step toward future therapies.
🔗 https://t.co/SKKPLqY6HM
@EmmaGuttman
If I told you I am making a tri-specific antibody that targets IL-1beta, IL-6, and TNF-alpha, every VC, investor, & pharma would run for the hills because of safety concerns.
Yet, vagus nerve stimulation can lower all of these cytokines safely and improve rheumatoid arthritis.
This is the sweet spot of neuroimmunology. Bending the therapeutic curve through immunologic tuning.
Lebrikizumab rapidly reduced IL-13–driven biomarkers and improved clinical outcomes in moderate-to-severe AD. This study by @emmaguttman and colleagues confirms IL-13 as a central driver of systemic inflammation and a prime target for precision therapy
🔗 https://t.co/y2jzvGS5G5
Today is a landmark moment in bioelectronic medicine and neuroimmunology. @KevinJTraceyMD and colleagues identified the inflammatory reflex over 25 years ago and now (today!) have delivered a FDA-approved device to treat autoimmunity. Viva la revolucion!
https://t.co/GyoHzp5vqI
This is one of the most brutally honest dialogues I have had about peer review. Peer review is valuable, but why? I am not sure we ask this question enough. It shouldn’t be a mindless, perfunctory, legacy enterprise. It should clearly and maybe even quantifiably bring value. Listen to my hot 🔥 el fuego take.
Kim Lab trainees have had an incredible 2025!
Lydia Zamidar accepted into MSTP (MD/PhD).
Daniel Yassky @dmyassky accepted into MD.
Victoria Le accepted into MD.
Kelsey Auyeung @kelsey_auyeung matched into Dermatology.
Anna Trier @AnnaMTrier matched into Dermatology.
Our lab continues batting 1000! Stay tuned!
@MSHSDerm@IcahnMountSinai@EmmaGuttman Honored and privileged to join Dr. Mark Lebwohl who directed the session "What's new in Dermatology" on the last day of the #AAD2025, with a packed house. I discussed "What's New in Topical Therapy" Thank you to Dr Lebwohl for the invitation! @BradMpH
🚨 News Alert 🚨
The FDA just released an important update regarding benzene in benzoyl peroxide products (https://t.co/Or0qA03wYO). See below for my thoughts and products to avoid:
It was a pleasure to reunite with great friends and colleagues at #AAD2025! Last Friday, our reception for Alumni and Friends of @MSHSDerm was an astonishing success, bringing ~500 dermatologists, and pharma members that celebrated our achievements with us. Thanks to all who attended! #dermtwitter #dermatology #NIH #Icahn #mountsinai #best
Hear from newly installed SOCS President @DrNadaE on the work of the #SkinofColorSociety and her vision for the future: https://t.co/lVnRLe7e6y via @hcplive
If you look at what the American Academy of Dermatology Annual Meeting looks like today, and if I could show you what it looked like in 2015, you would not believe me. Imagine a world without abrocotinib, dupilumab, lebrikizumab, tralokinumab, ruxolitinib, upadacitinib, and nemolizumab. Imagine no one caring about atopic dermatitis, prurigo nodularis, urticaria, pruritus. That was 2015. Today, itch has literally transformed the field of dermatology completely. If this sounds hyperbolic to you, then you probably missed your exit in Orlando and spent this weekend at Magic Kingdom.
Had a great time at the 2025 American Academy of Dermatology Meeting.
I discussed the evolving landscape and new developments in chronic pruritus of unknown origin, atopic dermatitis, chronic spontaneous urticaria, & prurigo nodularis #AAD2025#dermtwitter
Honored to be nominated for Vice-President elect of the AAD - I will
1. FIGHT FOR INFLATION-BASED MEDICARE REIMBURSEMENT
2. ADVOCATE FOR PRESERVING OF OUR SCOPE OF PRACTICE
3. ENSURE MISLEADING ADVERTISING IS COMBATTED
4. PROMOTE THE VALUE OF DERMATOLOGY